Management of residual mass in nonseminomatous germ cell tumors following chemotherapy
Advanced stage nonseminomatous testis cancer is commonly treated with chemotherapy and surgical resection. Patients with retroperitoneal residual masses >1cm following induction chemotherapy with normalized tumor markers should undergo a post-chemotherapy retroperitoneal lymph node dissection. Po...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2011-08-01
|
| Series: | Therapeutic Advances in Urology |
| Online Access: | https://doi.org/10.1177/1756287211418721 |
| id |
doaj-e6110c4e5b6d4651816776962abc682f |
|---|---|
| record_format |
Article |
| spelling |
doaj-e6110c4e5b6d4651816776962abc682f2020-11-25T03:24:02ZengSAGE PublishingTherapeutic Advances in Urology1756-28721756-28802011-08-01310.1177/1756287211418721Management of residual mass in nonseminomatous germ cell tumors following chemotherapySiamak DaneshmandHooman DjaladatCraig NicholsAdvanced stage nonseminomatous testis cancer is commonly treated with chemotherapy and surgical resection. Patients with retroperitoneal residual masses >1cm following induction chemotherapy with normalized tumor markers should undergo a post-chemotherapy retroperitoneal lymph node dissection. Post chemotherapy retroperitoneal residual mass less than 1 cm with normal markers may be considered as complete response, although the possibility of residual teratoma and viable germ cell tumor are not definitively ruled out. Excellent long term disease free survival following surveillance may justify this option as the treatment of choice in this cohort of patients.https://doi.org/10.1177/1756287211418721 |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Siamak Daneshmand Hooman Djaladat Craig Nichols |
| spellingShingle |
Siamak Daneshmand Hooman Djaladat Craig Nichols Management of residual mass in nonseminomatous germ cell tumors following chemotherapy Therapeutic Advances in Urology |
| author_facet |
Siamak Daneshmand Hooman Djaladat Craig Nichols |
| author_sort |
Siamak Daneshmand |
| title |
Management of residual mass in nonseminomatous germ cell tumors following chemotherapy |
| title_short |
Management of residual mass in nonseminomatous germ cell tumors following chemotherapy |
| title_full |
Management of residual mass in nonseminomatous germ cell tumors following chemotherapy |
| title_fullStr |
Management of residual mass in nonseminomatous germ cell tumors following chemotherapy |
| title_full_unstemmed |
Management of residual mass in nonseminomatous germ cell tumors following chemotherapy |
| title_sort |
management of residual mass in nonseminomatous germ cell tumors following chemotherapy |
| publisher |
SAGE Publishing |
| series |
Therapeutic Advances in Urology |
| issn |
1756-2872 1756-2880 |
| publishDate |
2011-08-01 |
| description |
Advanced stage nonseminomatous testis cancer is commonly treated with chemotherapy and surgical resection. Patients with retroperitoneal residual masses >1cm following induction chemotherapy with normalized tumor markers should undergo a post-chemotherapy retroperitoneal lymph node dissection. Post chemotherapy retroperitoneal residual mass less than 1 cm with normal markers may be considered as complete response, although the possibility of residual teratoma and viable germ cell tumor are not definitively ruled out. Excellent long term disease free survival following surveillance may justify this option as the treatment of choice in this cohort of patients. |
| url |
https://doi.org/10.1177/1756287211418721 |
| work_keys_str_mv |
AT siamakdaneshmand managementofresidualmassinnonseminomatousgermcelltumorsfollowingchemotherapy AT hoomandjaladat managementofresidualmassinnonseminomatousgermcelltumorsfollowingchemotherapy AT craignichols managementofresidualmassinnonseminomatousgermcelltumorsfollowingchemotherapy |
| _version_ |
1724603799254859776 |